[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349975-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349975-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","kdm5b-driven-glucose-metabolic-reprogramming-promotes-enzalutamide-resistance-in-prostate-cancer-via-the-lactate-hnrnpa1-lactylationar-v7-axis","KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/ hnRNPA1 lactylation/AR-V7 axis","","Resistance to enzalutamide (Enza) in castration-resistant prostate cancer (CRPC) worsens prognosis, yet the underlying mechanisms remain unclear despite high KDM5B expression in Enza-resistant disease. This study combines single-cell and multi-omics bioinformatics with in vitro and in vivo validation, using lactylation proteomics, CRISPR/Cas9 editing, ChIP, and dual-luciferase assays. KDM5B epigenetically suppresses PTEN, activating PI3K/Akt to increase PGK1-driven metabolic reprogramming and lactate production, which enhances p300-mediated hnRNPA1 lactylation and AR-V7 splicing. Inhibiting KDM5B or p300 reverses resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/kdm5b-driven-glucose-metabolic-reprogramming-promotes-enzalutamide-resistance-in-prostate-cancer-via-the-lactate-hnrnpa1-lactylationar-v7-axis/349975/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/kdm5b-driven-glucose-metabolic-reprogramming-promotes-enzalutamide-resistance-in-prostate-cancer-via-the-lactate-hnrnpa1-lactylationar-v7-axis/349975.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does KDM5B promote enzalutamide resistance in CRPC?","Question",{"text":63,"@type":64},"KDM5B epigenetically suppresses PTEN, activating PI3K/Akt signaling to upregulate PGK1 and drive metabolic reprogramming and lactate production, which supports resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does lactate play in the KDM5B mechanism?",{"text":68,"@type":64},"Lactate acts as a substrate for p300-mediated lactylation of hnRNPA1 at lysine 179, stabilizing hnRNPA1 by blocking NEDD4L-mediated ubiquitination and promoting AR-V7 splicing.",{"name":70,"@type":61,"acceptedAnswer":71},"Does blocking KDM5B or p300 affect drug resistance?",{"text":72,"@type":64},"Yes. Inhibiting KDM5B or p300 reverses enzalutamide resistance in vivo, indicating they are actionable nodes in the resistance pathway.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349975,1790473008,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Sun et al. Molecular Cancer (2026) 25:67 [https://doi.org/10.1186/s12943-026-02602-z](https://doi.org/10.1186/s12943-026-02602-z)  \nMolecular Cancer  \nRESEARCH Open Access  \nKDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/ hnRNPA1 lactylation/AR-V7 axis  \nRui Sun1,2†, Yong Huang1†, Hao He1†, Qiuchen Li1,3†, Linfeng Wang1,4†, Gaojie Zhang1,4†, Ziling Wei5, Yang Cao3, Jing Li3, Xianmin Wang6, Fan Yang6, Wenjun Chen1, Xiang Li7, Jiang Yu1, Siyuan Liu3, Congfeng Lei3, Yu Jiang8, Yueqiang Peng9, Huiyi Su10, Yingying Gao7*, Weiyang He1*, Lei Yang1* and Jiayu Liu 1*  \nAbstract  \nAims Resistance to enzalutamide (Enza) in castration-resistant prostate cancer (CRPC) is linked to poor prognosis. While KDM5B is highly expressed in Enza-resistant CRPC, the mechanisms of resistance remain poorly understood. Methods We applied an integrated approach to study KDM5B using bioinformatics analyses of single-cell and multi-omics data, along with in vitro and in vivo validation. We explored mechanisms through lactylation proteomics, CRISPR/Cas9 editing, ChIP, and dual-luciferase reporter assays.  \nResults KDM5B induces Enza resistance by epigenetically suppressing PTEN, which in turn activates the PI3K/ Akt signaling pathway to upregulate PGK1 and drive metabolic reprogramming and lactate production. Lactate acts as a substrate for p300-mediated lactylation of hnRNPA1 at lysine 179 (K179), stabilizing hnRNPA1 by blocking NEDD4L-mediated ubiquitination and promoting AR-V7 splicing. A potential positive feedback loop enhances this effect: KDM5B activates AR, and AR, in turn, increases KDM5B expression. Inhibiting KDM5B or p300 can reverse Enza resistance in vivo.  \n†Rui Sun, Yong Huang, Hao He, Qiuchen Li, Linfeng Wang and Gaojie Zhang contributed equally to this work.  \n*Correspondence:  \nYingying Gao [happygaoyingying@163.com](happygaoyingying@163.com)[ ](happygaoyingying@163.com)Weiyang He [202485@hospital.cqmu.edu.cn](202485@hospital.cqmu.edu.cn)[ ](202485@hospital.cqmu.edu.cn)Lei Yang [dr.yanglei@outlook.com](dr.yanglei@outlook.com)[ ](dr.yanglei@outlook.com)Jiayu Liu [urologistliu2022@163.com](urologistliu2022@163.com)  \nFull list of author information is available at the end of the article  \nIntroduction  \nProstate cancer (PCa) remains one of the leading causes of cancer-related deaths among men worldwide [1, 2]. Its incidence varies significantly across different regions. Androgen-receptor signaling inhibitors (ARSIs), such as enzalutamide (Enza), are the primary treatment for advanced PCa. These drugs work by blocking androgen receptor (AR) signaling to inhibit tumor growth. However, most patients eventually develop castration-resistant prostate cancer (CRPC) [3–5]. Resistance to ARSIs involves complex mechanisms, with one key factor being the development of constitutively active androgen receptor splice variants (AR-Vs) [6]. The most well-known  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/b","cbCainZ1xK53JnTJ","https://ap.wps.com/l/cbCainZ1xK53JnTJ","pdf",15399337,28,"English","# Abstract\n# Introduction\n# Conclusions\n# Highlights\n# Keywords","[{\"question\":\"How does KDM5B promote enzalutamide resistance in CRPC?\",\"answer\":\"KDM5B epigenetically suppresses PTEN, activating PI3K/Akt signaling to upregulate PGK1 and drive metabolic reprogramming and lactate production, which supports resistance.\"},{\"question\":\"What role does lactate play in the KDM5B mechanism?\",\"answer\":\"Lactate acts as a substrate for p300-mediated lactylation of hnRNPA1 at lysine 179, stabilizing hnRNPA1 by blocking NEDD4L-mediated ubiquitination and promoting AR-V7 splicing.\"},{\"question\":\"Does blocking KDM5B or p300 affect drug resistance?\",\"answer\":\"Yes. Inhibiting KDM5B or p300 reverses enzalutamide resistance in vivo, indicating they are actionable nodes in the resistance pathway.\"}]","KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/ hnRNPA1 lactylation/AR-V7 axis | PDF",1790086537,71,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b9429a49dd363a8666636ac28b90e30.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e534dbedff52d6bc798f02972e2e0d7.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/821ad9605327ba0898aca85069451265.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd53b035e1d0532859c20bd7006259ab.webp",980,1306]